Cell therapy has the potential to revise the paradigm, but little is known about the utility and risks of intracoronary cell administration soon after (ie, within 30 minutes of) reperfusion. No clinical data are available; most cell therapy clinical trials have infused cells 1 to 14 days post-AMI. By that time, cardiomyocytes at risk are already dead, 11 so that there is limited potential (if any) for myocardial salvage. Given the delays intrinsic to autologous tissue harvesting and cell processing, applications in the acute reperfusion phase will require allogeneic (off-the-shelf donor-derived) products. Preclinical studies of acutely administered allogeneic mesenchymal stem cells (MSCs) [12] [13] [14] or their precursors 15 have yielded variable results. Although heart-derived stem cells have been tested in both large animals and humans in chronic ischemic settings, 16, 17 the only studies in an acute ischemia/reperfusion model were in rats, 18, 19 where structural and functional outcomes were improved dramatically by the intracoronary infusion of cardiosphere-derived cells (CDCs) 20 minutes post-AMI. However, the 3-week end point in those studies made it impossible to separate cardioprotection from regeneration. 20 We sought to determine whether early infusion of allogeneic CDCs during reperfusion leads to myocardial protection in a clinically-relevant large animal model. To avoid possible ischemic postconditioning due to balloon inflations, and to mimic clinical reality, the initiation of therapy was delayed until 30 minutes post-reperfusion. We used a 48-hour end point to assess acute cardioprotection without the confounding effects of tissue regeneration, which may contribute to the final outcome of longer-term studies. 20 Figure 1 . Study protocols. Dose-escalation study (A) and pivotal study (B). AMI indicates acute myocardial infarction; CDCs, cardiosphere-derived cells; LVG, left ventriculography; and TnI, troponin I. 
Methods
For detailed methods, please see the Data Supplement. All animal studies were performed with approval from the Institutional Animal Care and Use Committee of the Cedars-Sinai Health System. Three separate experimental protocols were performed, as depicted schematically in Figure 1 and in Figure IA in the Data Supplement. A total of 15 Yucatan minipigs were studied in a dose-escalation study ( Figure 1A) ; 14 completed the pivotal study ( Figure 1B ); and 6 pigs were dedicated to the measurement of cell engraftment ( Figure IB in the Data Supplement). One Sinclair minipig (#0111) served as the donor for allogeneic heart-derived cells.
Cell Culture
Allogeneic CDCs were grown from a freshly-explanted heart obtained from 1 male Sinclair minipig.
Myocardial Infarct Creation and CDC Infusion
AMIs were created in adult Yucatan minipigs by inflation of an angioplasty balloon (TREK OTW 2-3 mm, Abbott Vascular, Santa Clara, CA) in the mid-left anterior descending artery (distal to the first diagonal branch) for 1.5 hours. Two studies were performed contemporaneously, involving a total of 39 minipigs: a dose-escalation study and a pivotal study. Because of acute reperfusion-related mortality (n=4) or technical reasons detailed in the Results section (n=6), 10 animals failed to complete the protocol.
Fifteen minipigs completed the dose-escalation study. Allogeneic CDCs (5, 7.5, and 10 million cells; n=5 pigs per dose) were formulated, frozen, and count-verified just prior to intracoronary infusion, which was performed 30 minutes post-reperfusion via an over-thewire balloon catheter, placed in the mid-left anterior descending artery. From the dose-escalation cell counts, post-thaw cell recoveries were 69.6±1.5% and cell viability 90.7±0.4% (n=7). The CDCs were administered in 3 equally divided cycles of balloon inflation separated by 3 minutes of deflation ( Figure 1A ). 16 Fourteen minipigs completed the pivotal study and were randomized to receive CDCs (n=4, with the cell infusion procedure as in the doseescalation study), placebo (n=5), or sham (n=5; balloon placement in the left anterior descending artery but without inflations, to exclude possible confounding effects related to ischemic postconditioning). The latter 2 groups, which had similar distributions and medians, were statistically indistinguishable (P=0.11-0.59 in all of histological and functional indicators) and thus were pooled as controls for the dosing study. The pivotal study was designed to mimic a clinical situation in which preformulated bags of CDCs containing a nominal dose of 12.5 million CDCs were frozen and thawed for administration, without cell counting prior to infusion; based on the post-thaw cell recovery data in the dose-escalation study, actual delivered total cell dosage was estimated at ≈8.7 millions.
Left Ventriculography
To measure global LV function and volumes, left ventriculography was performed before infusion and prior to euthanasia on day 2 using a pigtail catheter inserted retrogradely into the LV, with imaging in the 40° left anterior oblique projection (30 frames per second) using nonionic contrast (27-30 mL/3 s). LV volumes were indexed to body surface area, calculated as per the formula (body surface area=0.121 × body weight kg ^ 0.575). 21
Safety Evaluation (Coronary Flow and Arrhythmia)
Coronary flow was evaluated using thrombolysis in myocardial infarction (TIMI) score and corrected TIMI frame count grading systems. ECGs were recorded before induction of AMI, before CDC/ vehicle infusion, immediately after CDC/vehicle infusion, 1 hour after CDC/vehicle infusion (only in pivotal study), and prior to euthanasia to monitor for arrhythmias. In addition, ECGs were continuously monitored during intracoronary infusion and 1 hour postintervention for arrhythmias.
Histopathologic Evaluation
Two days after CDC or vehicle infusion, minipigs underwent median sternotomy and direct injection of dyes into the left atrium (Gentian Violet and Thioflavin T) to assess area at risk (AAR) and MVO. Then, minipigs were euthanized and the hearts explanted and sectioned into 1-cm-thick short-axis slices to measure AAR, IS, and MVO. Each slice was imaged digitally; IS and MVO areas were determined by manual tracing by a researcher blinded to treatment allocation. The fraction of the AAR within the total area was equated with its weight percent of the total weight of LV. MVO and IS were expressed as the weight percent of AAR.
Hemorrhage in the heart was investigated by hematoxylin and eosin staining of myocardial samples (fixed in 10% formalin, paraffin-embedded) obtained from the infarct, border, and remote myocardium; analysis was performed by an experienced cardiac pathologist (D.L.) blinded to treatment allocation, with an arbitrary scoring system (graded as none, mild, moderate, or severe using 0, 1, 2, and 3, respectively). To measure apoptotic cardiomyocytes, 8 μm sections from myocardial samples (fixed in 10% formalin, paraffin-embedded) obtained from the infarct, border, and remote zones underwent immunostaining for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; Roche 12156792910), α-sarcomeric actinin (ab9465 Abcam), and wheat-germ agglutinin (Invitrogen; to visualize cell borders). Vascular density was quantified in pigs euthanized 48 hours post-reperfusion. A total of 3 to 5 sections obtained from the border zones were evaluated per heart with immunostaining for Isolectin (Invitrogen I21411) and α-smooth muscle actin (ab5694 abcam). Alexa Fluor-conjugated secondary antibodies (Molecular Probes) were used and counterstained for 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI; Molecular Probes). Sections were imaged using a confocal laser scan microscope (Leica Microsystems), and images were processed by Leica Application Suite software. The border zone was defined as the region at the edges of the scar (comprising areas of both viable and scarred myocardium).
Blood Examination
In the pivotal study, blood draws were performed 24 hours after CDC or vehicle infusion and prior to euthanasia (48 hours) to measure serum troponin I as a marker of cardiac injury.
Engraftment Study
Engraftment was measured ( Figure IA in the Data Supplement) as described. 22 Luciferase-labeled CDCs were delivered via intracoronary infusion (n=6) 15 minutes post-reperfusion. Animals were euthanized 15 minutes (n=3) or 48 hours (n=3) later and tissues were taken for luciferase measurement.
Statistical Analysis
Pooled data are expressed as box plots. Mann-Whitney U test was used for comparisons between 2 independent groups. Multiple groups were compared using Kruskal-Wallis test with Bonferroni post hoc testing. P<0.05 was considered statistically significant.
Results

Adverse Events and Mortality
In the dose-escalation study ( Table I in the Data Supplement), 1 animal of 18 (6%) died of cardiogenic shock immediately after left ventriculography post-reperfusion. Two pigs were excluded due to technical failure or incomplete dye study. There was no further mortality (0%), nor were any adverse events noted during the infusion procedure in either group. In the pivotal study, 3 of 21 animals (14%) died during creation of AMI due to ventricular arrhythmia; 3 pigs were excluded due to technical failure of AMI creation or incomplete dye study. One pig was excluded due to incidentally-discovered hypertrophic cardiomyopathy at necropsy. Thus, a total of 14 pigs completed the pivotal study. There was no further mortality within the protocol (0%), nor were there any other adverse events ( Table II in To assess differences of treatment effects with escalating doses of allogeneic CDCs, we measured cardiac function and volumes by left ventriculography. Representative ventriculograms 48 hours post-CDC treatment show amelioration of LV anterior wall motion compared with control, especially in the 7.5 million pigs (Figure 2A, yellow arrows) . Although the changes in the ejection fraction from baseline to 48 hours post-CDC infusion were not significantly different among groups ( Figure 2B) , minipigs in control and 5 million groups underwent progressive LV dilatation (both at end-diastole [ Figure 2C ] and end-systole [ Figure 2D ]); the change in left ventricular end-diastolic volume index was significantly attenuated in the pigs that received 7.5 million cells ( Figure 2C ). In addition, we evaluated AAR, IS, and MVO by dye study 48 hours post-infusion. Although AAR in the 4 groups was comparable, IS and MVO (as a % of AAR) were smaller (7.5 million) or strongly tended to be smaller (10 million) than in the control or 5 million groups (Figure 2E-2G) .
Dose-Escalation Study
Functional and Histological Benefits of CDC Infusion With Optimal Dose
Pathological Assessment and Cytoprotective Effect of CDCs With Optimal Dosage
The extent of intramyocardial hemorrhage was indistinguishable in all groups ( Figure IIA and IIB in the Data Supplement). By contrast, CDC infusion blunted apoptosis as revealed by TUNEL staining ( Figure 3A ). The number of TUNEL-positive cardiomyocytes in the border zone was lower in all CDC groups than in control (P=0.002; Figure 3B , left panel), a pattern repeated, albeit with less significance (P=0.052), in the ischemic zone ( Figure 3B, right panel) .
As for coronary flow evaluation, absolute corrected TIMI frame counts post-infusion were different in the 4 groups (P<0.05; Table I in the Data Supplement) , with significant pairwise differences between control and 10 million groups, but no differences among control, 5 million, or 7.5 million groups ( Figure III in the Data Supplement).
Overall, although there is a tendency for the 10 million group to be worse than the 7.5 million group, both 7.5 and 10 million groups seem to be better than control or 5 million group in terms of functional, histological, and safety concern. We conclude that 7.5 to 10 millions is the optimal therapeutic dosage range.
Pivotal Study
Having established a target dosage range of 7.5 to 10 million CDCs, we performed a pivotal preclinical study with animals randomized to placebo, sham, or CDC groups. The CDC group mimicked the clinical situation in which a preformulated bag is acutely thawed for infusion at the site of reperfusion. It is clinically unrealistic to perform cell counting prior to product release in the AMI setting, so that infusion bags filled with 12.5 million CDCs were used, without on-site cell counting and recognizing that some of the cell product would be retained in the dead space of the bags and tubing. From the cell count findings in the dose-escalation study, actual delivered cell dosage was estimated at ≈8.7 millions, well within the desired therapeutic range of 7.5 to 10 millions.
Histological Efficacy of Intracoronary Infusion of CDCs as Adjunctive Therapy to Reperfusion
To assess the acute benefit of allogeneic CDCs, we evaluated histological efficacy of CDCs by dye study at 48 hours. Figure 4A shows representative slices stained with gentian violet to delineate AAR and 2,3,5-triphenyl tetrazolium chloride to quantify IS. 23 The infarcted zone (white/yellow) within the AAR (brick-red) is visibly smaller than that of sham or placebo. The AAR/LV (as a % of the LV) was similar among all 3 groups, indicating comparable degrees of initial injury ( Figure 4B) . IS (as a % of AAR) was smaller in the CDC group (59.7%, P<0.05 versus sham and placebo) compared with sham (81.0%) or placebo (80.3%; Figure 4C ). In addition, IS (as a % of the LV) was also smaller in the CDC group (12.5%, P<0.05 versus sham and placebo) than in sham (19.9%) or placebo (18.5%) groups ( Figure 4D ).
We also evaluated MVO in the pivotal study. Figure 4E shows ultraviolet epifluorescent images of representative slices stained with thioflavin T; here, the MVO area appears dark as it has not taken up the infused thioflavin and thus is nonfluorescent. MVO area is distinctly smaller in the CDCtreated pig than in sham or placebo, as verified by the pooled data in Figure 4F .
Functional Efficacy in the Acute Phase of Intracoronary Infusion of Allogeneic CDCs
We assessed the acute treatment effects of allogeneic CDCs on LV function and volumes by left ventriculography. Although the change of ejection fraction ( Figure 5A ) between baseline and 48 hours postintervention was similar in all groups, minipigs in sham and placebo groups underwent progressive LV dilatation ( Figure 5B and 5C ), which was attenuated in CDCtreated pigs.
Safety Evaluation of Intracoronary Infusion of CDCs
Consistent with the structural evidence of reduced myocardial injury (Figure 4) , CDC treatment decreased serum troponin I level measured 24 hours post-MI ( Figure 5D ). These data support the conclusion that CDCs exert a cardioprotective effect, even when cell administration is delayed to 30 minutes after reperfusion.
Pathological Assessment and Cytoprotective Effect in Pivotal Study
The extent of intramyocardial hemorrhage was comparable in the 3 experimental groups ( Figure IVA and IVB in the Data Supplement). We also quantified apoptosis in the 3 groups by staining border and infarct zone samples for TUNEL ( Figure 6A ). Consistent with the results of the dose-escalation study, the percentages of TUNEL-positive myocytes in the border (49.5%) was lower in CDC-treated hearts than in sham (68.8%) or placebo (64.3%; Figure 6B, upper panel) . Here, we additionally see unequivocal benefit in the infarct zone (Figure 6B, lower panel) .
Measurement of CDC Engraftment by Luciferase
Cardiac engraftment of CDCs decreased from 39.9±9.6% (n=3) at 15 minutes to 3.7±1.6% (n=3) at 48 hours. There was a significant difference in engraftment at the 2 time points ( Figure IB in the Data Supplement).
Assessment of Vascularization
We analyzed vessel density in border zone samples by immunostaining in dose-escalation and pivotal studies ( Figure VA and VB in the Data Supplement). Quantification of vessel density did not reveal any significant differences among groups.
Discussion
Early and successful myocardial reperfusion with percutaneous coronary intervention is the most effective strategy for AMI. 24, 25 However, reperfusion itself has the potential to aggravate injury, which may in part explain why the incidence of HF after AMI approaches 25%. 26 Here, we have demonstrated a novel benefit of infused CDCs administered 30 minutes after reperfusion: such treatment decreased IS and MVO in pigs with AMI. Our findings are notable for 2 reasons: first, CDCs work despite having been administered relatively late after reperfusion. No other cardioprotective modality has successfully reduced IS without pretreatment (ischemic or pharmacological preconditioning) or immediate intervention on reopening the affected artery (ischemic postconditioning). Second, our study design, with 48-hour structural and functional end points, guarantees that we are studying acute cardioprotection; otherwise, it is impossible to exclude a partial or dominant contribution from longer-term regenerative effects of the cells, which are evident only weeks after treatment. 20 Given the novelty of the phenomenon described here, we call it cellular postconditioning.
Influence of Postconditioning on Reperfusion Injury
Ischemic postconditioning, described by Zhao et al, 27 is a cardioprotective phenomenon which can be recruited by applying intermittent cycles of ischemia immediately after reperfusion. There is some inconsistency in the literature as to how long a delay after reperfusion can be imposed while retaining the benefits of ischemic postconditioning, with most studies claiming rapid evanescence (<10 minutes), 9, 10 but one showing that delays of ≤30 minutes may be possible. 28 To see whether ischemic postconditioning might have influenced our own results, we compared the placebo group (where 3 cycles of stop-flow ischemia were applied without cell infusion) with the sham group, which simply had a catheter placed in the left anterior descending artery without intermittent balloon inflations. Results in the 2 groups were indistinguishable, ruling out a contributory role for ischemic postconditioning in our protocol. Thus, the cardioprotective effects of CDCs infused at 30 minutes are distinct from those of ischemic postconditioning. Not only is the trigger different (cells versus ischemia) but also the window of treatment opportunity is longer. Such a delay is consistent with clinical reality: when a patient presents with AMI, the immediate focus is on prompt recanalization of the occluded vessel. Only after patency has been re-established and a stent deployed will the typical clinician consider adjunctive therapy; the allowance of 30 minutes to initiate infusion accommodates decision to treat, product thawing, and technical preparation for administration.
Feasibility and Safety of Intracoronary Infusion of CDCs in AMI
In addition to the above considerations, translation will be facilitated by the fact that we used standard clinical equipment and intracoronary infusion for cell transplantation. Intracoronary infusion can be performed in a minimally invasive manner and has been safely used in numerous preclinical studies and clinical trials. 17, 18, 22, 29, 30 Some previous large animal studies have questioned the safety of intracoronary infusion of stem cells post-MI, with decreased coronary flow and elevation of cardiac enzymes attributed to microvascular plugging. [12] [13] [14] 31 Houtgraaf et al 15 had more favorable results after careful attention to cell dosage, size, and infusion rate. In terms of cell dosage, we have validated the safety of 12.5 million intracoronary CDCs in pigs with chronic ischemic cardiomyopathy, and 25 million CDCs administered to post-MI patients in the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial, without complications such as microembolization. 18, 22 Cell dosage must be carefully validated in the acute phase of reperfusion post-MI, given the presence of infarct-related microvascular injury. 32 As for cell size, although it is reported that the average diameter of MSCs is 30 to 50 μm, 33 CDCs are ≈20 μm in diameter. 22 In addition, previous studies demonstrated microinfarction or slow-flow phenomena at high infusion rates and high cell doses (eg, 50 million cells at a rate of 1.5 million cells/min). 12, 14 On the other hand, Houtgraaf et al 15 found that slow infusion of mesenchymal progenitor cells (0.5 million cells/min) enabled intracoronary infusion of 50 million cells without compromise of coronary flow. Here, we infused relatively low cell numbers at rates of 0.8 to 1.6 million cells/min following reperfusion; 7.5 to 10 million CDCs at rates of 1.25 to 1.6 million cells/min were well-tolerated and therapeutically active, in general agreement with Houtgraaf et al. 15 Our studies differ in that we delayed cell infusion until 30 minutes after reflow (Houtgraaf et al 15 
Potential Mechanism of Benefit in CDC-Treated Hearts
In the vast majority of experimental studies, the number of differentiated myocytes derived from transplanted stem cells is too small to account for the observed improvements in cardiac function. 34 Thus, the prevailing concept of stem cell efficacy has shifted toward the paracrine hypothesis, according to which the transplanted cells are proposed to produce soluble factors that are beneficial to the infarcted heart. 35 Indeed, skeletal myoblasts, 36 bone marrow-derived cells, 37 and cardiacderived cells 38 produce and secrete a broad variety of cytokines. In small comparative studies, CDCs outperformed MSCs in vitro 39 and in vivo. 40 In a head-to-head comparison of 4 different cell types (CDCs, bone marrow-derived mononuclear cells, bone marrow-derived MSCs, and adipose-derived MSCs) in the same animal model in the same laboratory, CDCs emerged as superior in terms of paracrine factor secretion, angiogenesis, cardiomyogenic differentiation, ischemic tissue preservation, antiremodeling effects, and functional benefit post-MI. 41 Potential cardioprotective effects of paracrine factors include antiapoptotic effects on resident myocytes, upregulation of angiogenesis, modulation of inflammatory processes resulting in better infarct healing, improvements of cardiac metabolism and contractility, promotion of cardiomyocyte cell cycle re-entry, and induction of secondary humoral effects in the host tissue. 42, 43 Here, we observed histological benefits including reduction of IS, MVO, and apoptotic cardiomyocytes only 48 hours post-cell transplantation, which is consistent with paracrine effects but not differentiation of transplanted cells into cardiomyocytes or vessels, as demonstrated in Figures I and V in the Data Supplement. Beyond these considerations, however, the present study provides no insight into the detailed mechanisms of benefit of cellular postconditioning.
Limitations
This study has several limitations. First, this model is one of iatrogenic AMI caused by balloon occlusion. The pathophysiological situation differs from acute coronary syndrome with regard to influence of microembolization derived from atherosclerotic plaque or thrombus. Also, the well-defined duration of ischemia here differs from the clinical situation, which is much more heterogeneous. Second, we infused allogeneic CDCs in this study, but did not look for a potential immune response given the short-term nature of the end points. However, allogeneic heart-derived cells have been transplanted without eliciting deleterious immune reactions in previous reports. 16, 44, 45 Although off-the-shelf allogeneic products are clearly necessary for the infusion of cells immediately after percutaneous coronary intervention, we need to test the safety concerns of allogeneic cells in longer-term experiments.
Conclusions
We demonstrate a cardioprotective effect of CDCs after reperfusion using a large animal model and strategies that are compatible with standard clinical practice. These results not only motivate potential clinical exploration of acutely-administered CDCs in AMI but also the further exploration of long-term efficacy and mechanism of benefit.
